Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Update Il y a 4 ans
Reference: NCT00431561

Woman and Man

Extract

In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade glioma.


Inclusion criteria

  • Glioblastoma ,Anaplastic Astrocytoma


Links